CS
ACAD icon

Candriam SCA’s Acadia Pharmaceuticals ACAD Stock Holding History

Candriam SCA’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-537,601
Closed -$11.5M – 686
2025
Q3 		$11.5M Buy
+537,601
New +$12.7M 0.06% 255
2024
Q2 		– Sell
-405,751
Closed -$7.5M – 688
2024
Q1 		$7.5M Buy
+405,751
New +$10.1M 0.05% 289
2022
Q2 		– Sell
-230,417
Closed -$5.58M – 776
2022
Q1 		$5.58M Sell
230,417
-45,143
-16% -$1.09M 0.04% 331
2021
Q4 		$6.43M Hold
275,560
– – 0.04% 311
2021
Q3 		$4.58M Hold
275,560
– – 0.03% 415
2021
Q2 		$6.72M Sell
275,560
-23,328
-8% -$527K 0.05% 350
2021
Q1 		$15.3M Hold
298,888
– – 0.13% 179
2020
Q4 		$16M Sell
298,888
-10,112
-3% -$502K 0.13% 181
2020
Q3 		$12.7M Buy
309,000
+70,000
+29% +$3.02M 0.12% 190
2020
Q2 		$11.6M Buy
239,000
+159,000
+199% +$7.63M 0.12% 196
2020
Q1 		$3.35M Hold
80,000
– – 0.04% 445
2019
Q4 		$3.42M Buy
+80,000
New +$3.48M 0.04% 459
2019
Q1 		– Sell
-173,700
Closed -$2.81M – 789
2018
Q4 		$2.81M Buy
173,700
+38,000
+28% +$738K 0.04% 390
2018
Q3 		$2.82M Buy
135,700
+3,700
+3% +$58.2K 0.04% 426
2018
Q2 		$2.02M Buy
132,000
+55,000
+71% +$981K 0.03% 483
2018
Q1 		$1.73M Hold
77,000
– – 0.03% 507
2017
Q4 		$2.32M Hold
77,000
– – 0.04% 428
2017
Q3 		$2.9M Sell
77,000
-50,000
-39% -$1.63M 0.05% 377
2017
Q2 		$3.54M Buy
127,000
+66,000
+108% +$1.97M 0.07% 339
2017
Q1 		$2.1M Buy
+61,000
New +$2.15M 0.04% 431
2015
Q4 		– Sell
-93,200
Closed -$3.08M – 557
2015
Q3 		$3.08M Sell
93,200
-48,800
-34% -$2.03M 0.08% 273
2015
Q2 		$5.95M Sell
142,000
-11,000
-7% -$426K 0.12% 209
2015
Q1 		$4.99M Sell
153,000
-12,000
-7% -$412K 0.1% 254
2014
Q4 		$5.24M Buy
+165,000
New +$4.68M 0.11% 221

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Candriam SCA's ACAD Position: Q4 2025 in Review

Candriam SCA sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 537,601 shares — an estimated $11.5M sold.

Candriam SCA first reported a position in ACAD in Q4 2014 and held it in 24 quarters. The position peaked at $16M in Q4 2020. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Candriam SCA reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Candriam SCA sold 537,601 Acadia Pharmaceuticals shares in Q4 2025, an estimated $11.5M.
  • Candriam SCA first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 24 quarters.
  • Candriam SCA's Acadia Pharmaceuticals position peaked at $16M in Q4 2020.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Candriam SCA's 13F filing for Q4 2025, filed 13 Feb 2026.